Myriad Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-49,000
Closed -$509K 93
2020
Q3
$509K Buy
+49,000
New +$509K 0.11% 44

Other funds holding STLN

Myriad Asset Management's STLN Position: Q4 2020 in Review

Myriad Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2020, closing a stake of 49,000 shares — an estimated $509K sold.

Myriad Asset Management first reported a position in STLN in Q3 2020 and held it in 1 quarter. The position peaked at $509K in Q3 2020. 49 funds tracked by Wall St. Rank hold STLN as of Q4 2020.

  • Myriad Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Myriad Asset Management sold 49,000 Starling Oncology Institute, Inc. Common Stock shares in Q4 2020, an estimated $509K.
  • Myriad Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Myriad Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $509K in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2020.

Based on Myriad Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.